Neumora Therapeutics (NASDAQ:NMRA) Insider Sells $21,947.40 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 6,165 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.56, for a total transaction of $21,947.40. Following the completion of the sale, the insider owned 82,770 shares of the company’s stock, valued at approximately $294,661.20. The trade was a 6.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Neumora Therapeutics Trading Down 3.1%

Shares of NMRA traded down $0.11 during midday trading on Thursday, hitting $3.48. 1,491,798 shares of the stock were exchanged, compared to its average volume of 2,331,130. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The firm has a market cap of $581.47 million, a P/E ratio of -2.37 and a beta of 3.20. Neumora Therapeutics, Inc. has a 52-week low of $0.61 and a 52-week high of $3.65. The stock has a fifty day simple moving average of $2.15 and a 200 day simple moving average of $2.05.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NMRA. Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research report on Monday, January 5th. Leerink Partners started coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price on the stock. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Needham & Company LLC upped their price objective on Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Finally, Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $4.00 to $7.00 in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.13.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NMRA. Siren L.L.C. grew its holdings in Neumora Therapeutics by 44.3% during the 4th quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock worth $11,257,000 after acquiring an additional 1,930,500 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after purchasing an additional 1,608,266 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Neumora Therapeutics by 24.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock worth $2,588,000 after purchasing an additional 281,926 shares during the last quarter. Ikarian Capital LLC lifted its position in shares of Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock worth $2,288,000 after purchasing an additional 1,265,910 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Neumora Therapeutics by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 1,003,746 shares of the company’s stock worth $1,797,000 after purchasing an additional 34,818 shares in the last quarter. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.